BEKSAÇ, M. Et Al. 2019. Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10 .

BEKSAÇ, M., Seval, G. C., PAYDAŞ, S., Tuglular, T. F., ARSLAN, Ö., GÖKER, H., ... KAYNAR, L.(2019). Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10.

BEKSAÇ, MERAL Et Al. "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10, 2019

BEKSAÇ, MERAL Et Al. "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10, 2019

BEKSAÇ, M. Et Al. (2019) . "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10.

@article{article, author={MERAL BEKSAÇ Et Al. }, title={Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2019}